Form 4: Cumberland Pharmaceuticals Director Kenneth Krogulski Executes Pre-Planned Stock Purchases

Director Kenneth Krogulski reports a series of common stock acquisitions through a pre-arranged 10b5-1 trading plan.

Summary

• Kenneth Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), has reported multiple purchases of common stock between July 1, 2024, and July 31, 2024.
• These transactions were executed automatically under a Rule 10b5-1 trading plan adopted on March 13, 2024.
• The purchases involved varying amounts of stock at prices ranging from $1.45 to $1.52 per share.
• The total number of shares beneficially owned by Krogulski following these transactions increased from 243,778 to 247,907.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock purchases under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's performance.

Positives

• The director's consistent purchases may signal confidence in the company's prospects.
• The use of a 10b5-1 trading plan ensures compliance with insider trading regulations.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider trading activity. It's common for corporate insiders to use 10b5-1 plans to buy or sell shares over time, avoiding accusations of trading on non-public information.

Stakeholder Impact

• The stock purchases could have a slightly positive impact on shareholder sentiment.

Key Dates